These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

721 related items for PubMed ID: 26819103

  • 1. Evaluation of (68)Ga-DOTA-TOC PET/CT for the detection of duodenopancreatic neuroendocrine tumors in patients with MEN1.
    Morgat C, Vélayoudom-Céphise FL, Schwartz P, Guyot M, Gaye D, Vimont D, Schulz J, Mazère J, Nunes ML, Smith D, Hindié E, Fernandez P, Tabarin A.
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1258-66. PubMed ID: 26819103
    [Abstract] [Full Text] [Related]

  • 2. Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle.
    Nilica B, Waitz D, Stevanovic V, Uprimny C, Kendler D, Buxbaum S, Warwitz B, Gerardo L, Henninger B, Virgolini I, Rodrigues M.
    Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1585-92. PubMed ID: 26922350
    [Abstract] [Full Text] [Related]

  • 3. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy.
    Gabriel M, Oberauer A, Dobrozemsky G, Decristoforo C, Putzer D, Kendler D, Uprimny C, Kovacs P, Bale R, Virgolini IJ.
    J Nucl Med; 2009 Sep; 50(9):1427-34. PubMed ID: 19690033
    [Abstract] [Full Text] [Related]

  • 4. 68Ga-DOTATOC PET/CT in the localization of head and neck paraganglioma compared with 18F-DOPA PET/CT and 123I-MIBG SPECT/CT.
    Kroiss AS, Uprimny C, Shulkin BL, Gruber L, Frech A, Url C, Riechelmann H, Sprinzl GM, Thomé C, Treglia G, Kjaer A, Fraedrich G, Virgolini IJ.
    Nucl Med Biol; 2019 Apr; 71():47-53. PubMed ID: 31152973
    [Abstract] [Full Text] [Related]

  • 5. Added value of [68Ga]Ga-DOTA-TOC PET/CT for characterizing pancreatic neuroendocrine neoplasms: a comparison with contrast-enhanced CT and/or MRI in a large study cohort.
    Yoo J, Kim SH, Jeon SK, Bae JS, Han JK.
    Eur Radiol; 2021 Oct; 31(10):7734-7745. PubMed ID: 33787974
    [Abstract] [Full Text] [Related]

  • 6. Comparison of (68)Ga-DOTA-Tyr(3)-octreotide and (18)F-fluoro-L-dihydroxyphenylalanine positron emission tomography in neuroendocrine tumor patients.
    Putzer D, Gabriel M, Kendler D, Henninger B, Knoflach M, Kroiss A, Vonguggenberg E, Warwitz B, Virgolini IJ.
    Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):68-75. PubMed ID: 20168288
    [Abstract] [Full Text] [Related]

  • 7. Functional imaging in neuroendocrine tumors: assessment of molecular heterogeneity using [68Ga]Ga-DOTA-TOC and [18F]FDG PET/CT.
    Nogareda Seoane Z, Mallón Araújo MC, Calatayud Cubes A, Barberán Corral C, Domínguez Novoa Y, Cousillas Castiñeira A, Martínez Lago N, de Matías Leralta JM, Pubul Nuñez V.
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2024 Feb; 43(3):500011. PubMed ID: 38643835
    [Abstract] [Full Text] [Related]

  • 8. Comparison of 68Ga-Dotatate PET/CT and 18F-FDOPA PET/CT for the diagnosis of pancreatic neuroendocrine tumors in a MEN1 patient.
    Jullien M, Reichert T, D'Anella P, Castinetti F, Barlier A, Brue T, Taieb D, Cuny T.
    Ann Endocrinol (Paris); 2020 Feb; 81(1):39-43. PubMed ID: 31982106
    [Abstract] [Full Text] [Related]

  • 9. Functional imaging in differentiating bronchial masses: an initial experience with a combination of (18)F-FDG PET-CT scan and (68)Ga DOTA-TOC PET-CT scan.
    Kumar A, Jindal T, Dutta R, Kumar R.
    Ann Nucl Med; 2009 Oct; 23(8):745-51. PubMed ID: 19784877
    [Abstract] [Full Text] [Related]

  • 10. Role of (68)Ga-DOTATATE PET/CT in patients with multiple endocrine neoplasia type 1 (MEN1).
    Lastoria S, Marciello F, Faggiano A, Aloj L, Caracò C, Aurilio M, D'Ambrosio L, Di Gennaro F, Ramundo V, Camera L, De Luca L, Fonti R, Napolitano V, Colao A.
    Endocrine; 2016 Jun; 52(3):488-94. PubMed ID: 26242621
    [Abstract] [Full Text] [Related]

  • 11. Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotide.
    Putzer D, Kroiss A, Waitz D, Gabriel M, Traub-Weidinger T, Uprimny C, von Guggenberg E, Decristoforo C, Warwitz B, Widmann G, Virgolini IJ.
    Eur J Nucl Med Mol Imaging; 2013 Feb; 40(3):364-72. PubMed ID: 23151915
    [Abstract] [Full Text] [Related]

  • 12. Diagnostic performance and impact on patient management of 68Ga-DOTA-TOC PET/CT for detecting osteomalacia-associated tumours.
    Paquet M, Gauthé M, Zhang Yin J, Nataf V, Bélissant O, Orcel P, Roux C, Talbot JN, Montravers F.
    Eur J Nucl Med Mol Imaging; 2018 Sep; 45(10):1710-1720. PubMed ID: 29532101
    [Abstract] [Full Text] [Related]

  • 13. A retrospective comparison between 68Ga-DOTA-TOC PET/CT and 18F-DOPA PET/CT in patients with extra-adrenal paraganglioma.
    Kroiss A, Putzer D, Frech A, Decristoforo C, Uprimny C, Gasser RW, Shulkin BL, Url C, Widmann G, Prommegger R, Sprinzl GM, Fraedrich G, Virgolini IJ.
    Eur J Nucl Med Mol Imaging; 2013 Dec; 40(12):1800-8. PubMed ID: 24072345
    [Abstract] [Full Text] [Related]

  • 14. Vertebral metastases from neuroendocrine tumours: How to avoid false positives on 68Ga-DOTA-TOC PET using CT pattern analysis?
    Gauthé M, Testart Dardel N, Ruiz Santiago F, Ohnona J, Nataf V, Montravers F, Talbot JN.
    Eur Radiol; 2018 Sep; 28(9):3943-3952. PubMed ID: 29532242
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of [68Ga]Ga-DATA-TOC for imaging of neuroendocrine tumours: comparison with [68Ga]Ga-DOTA-NOC PET/CT.
    Yadav D, Ballal S, Yadav MP, Tripathi M, Roesch F, Bal C.
    Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):860-869. PubMed ID: 31754796
    [Abstract] [Full Text] [Related]

  • 16. Utility of FDG-PET Imaging for Risk Stratification of Pancreatic Neuroendocrine Tumors in MEN1.
    Kornaczewski Jackson ER, Pointon OP, Bohmer R, Burgess JR.
    J Clin Endocrinol Metab; 2017 Jun 01; 102(6):1926-1933. PubMed ID: 28323985
    [Abstract] [Full Text] [Related]

  • 17. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT.
    Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, Kovacs P, Von Guggenberg E, Bale R, Virgolini IJ.
    J Nucl Med; 2007 Apr 01; 48(4):508-18. PubMed ID: 17401086
    [Abstract] [Full Text] [Related]

  • 18. Dual tracer functional imaging of gastroenteropancreatic neuroendocrine tumors using 68Ga-DOTA-NOC PET-CT and 18F-FDG PET-CT: competitive or complimentary?
    Naswa N, Sharma P, Gupta SK, Karunanithi S, Reddy RM, Patnecha M, Lata S, Kumar R, Malhotra A, Bal C.
    Clin Nucl Med; 2014 Jan 01; 39(1):e27-34. PubMed ID: 24217539
    [Abstract] [Full Text] [Related]

  • 19. EUS is superior for detection of pancreatic lesions compared with standard imaging in patients with multiple endocrine neoplasia type 1.
    van Asselt SJ, Brouwers AH, van Dullemen HM, van der Jagt EJ, Bongaerts AH, Kema IP, Koopmans KP, Valk GD, Timmers HJ, de Herder WW, Feelders RA, Fockens P, Sluiter WJ, de Vries EG, Links TP.
    Gastrointest Endosc; 2015 Jan 01; 81(1):159-167.e2. PubMed ID: 25527055
    [Abstract] [Full Text] [Related]

  • 20. Simultaneous (68)Ga-DOTA-TOC PET/MRI with gadoxetate disodium in patients with neuroendocrine tumor.
    Hope TA, Pampaloni MH, Nakakura E, VanBrocklin H, Slater J, Jivan S, Aparici CM, Yee J, Bergsland E.
    Abdom Imaging; 2015 Aug 01; 40(6):1432-40. PubMed ID: 25820755
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.